On Nov 26, major Wall Street analysts update their ratings for $BridgeBio Pharma (BBIO.US)$, with price targets ranging from $45 to $55.
Goldman Sachs analyst Paul Choi maintains with a buy rating, and adjusts the target price from $50 to $55.
BofA Securities analyst Jason Zemansky maintains with a buy rating, and maintains the target price at $45.
Citi analyst David Lebowitz maintains with a buy rating, and maintains the target price at $45.
UBS analyst Eliana Merle maintains with a buy rating, and adjusts the target price from $47 to $54.
Evercore analyst Cory Kasimov maintains with a buy rating, and maintains the target price at $45.
Furthermore, according to the comprehensive report, the opinions of $BridgeBio Pharma (BBIO.US)$'s main analysts recently are as follows:
The FDA's approval of BridgeBio's stabilizer acoramidis as Attruby for ATTR-CM, coming before the anticipated November 29 PDUFA deadline, was celebrated as a significant achievement, marking the company's transition into a commercial entity with an optimal label. The potential for ATTR-CM remains, according to analysts, still largely underestimated.
Here are the latest investment ratings and price targets for $BridgeBio Pharma (BBIO.US)$ from 10 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月26日，多家华尔街大行更新了$BridgeBio Pharma (BBIO.US)$的评级，目标价介于45美元至55美元。
高盛集团分析师Paul Choi维持买入评级，并将目标价从50美元上调至55美元。
美银证券分析师Jason Zemansky维持买入评级，维持目标价45美元。
花旗分析师David Lebowitz维持买入评级，维持目标价45美元。
瑞士银行分析师Eliana Merle维持买入评级，并将目标价从47美元上调至54美元。
Evercore分析师Cory Kasimov维持买入评级，维持目标价45美元。
此外，综合报道，$BridgeBio Pharma (BBIO.US)$近期主要分析师观点如下：
以下为今日10位分析师对$BridgeBio Pharma (BBIO.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
